Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.55 Million SEK | -54.48% |
| 2022 | 31.97 Million SEK | 177.8% |
| 2021 | 11.5 Million SEK | 38.41% |
| 2020 | 8.31 Million SEK | 67.69% |
| 2019 | 4.95 Million SEK | -43.11% |
| 2018 | 8.71 Million SEK | -17.57% |
| 2017 | 10.57 Million SEK | -7.06% |
| 2016 | 11.37 Million SEK | 118.88% |
| 2015 | 5.19 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 17.32 Million SEK | -15.27% |
| 2024 Q1 | 19.13 Million SEK | 31.46% |
| 2024 Q2 | 20.44 Million SEK | 6.87% |
| 2023 FY | 14.55 Million SEK | -54.48% |
| 2023 Q3 | 22.14 Million SEK | -3.68% |
| 2023 Q2 | 22.99 Million SEK | -5.64% |
| 2023 Q4 | 14.55 Million SEK | -34.28% |
| 2023 Q1 | 24.36 Million SEK | -23.79% |
| 2022 Q2 | 27.95 Million SEK | 6.65% |
| 2022 Q4 | 31.97 Million SEK | -9.78% |
| 2022 FY | 31.97 Million SEK | 177.8% |
| 2022 Q1 | 26.21 Million SEK | 127.77% |
| 2022 Q3 | 35.43 Million SEK | 26.76% |
| 2021 Q1 | 7.89 Million SEK | -5.01% |
| 2021 FY | 11.5 Million SEK | 38.41% |
| 2021 Q4 | 11.5 Million SEK | 32.43% |
| 2021 Q3 | 8.69 Million SEK | -9.68% |
| 2021 Q2 | 9.62 Million SEK | 21.81% |
| 2020 Q4 | 8.31 Million SEK | 18.01% |
| 2020 FY | 8.31 Million SEK | 67.69% |
| 2020 Q1 | 5.62 Million SEK | 13.34% |
| 2020 Q2 | 7.36 Million SEK | 30.96% |
| 2020 Q3 | 7.04 Million SEK | -4.27% |
| 2019 Q1 | 3.97 Million SEK | -54.36% |
| 2019 Q4 | 4.95 Million SEK | 16.4% |
| 2019 Q3 | 4.26 Million SEK | 1.38% |
| 2019 FY | 4.95 Million SEK | -43.11% |
| 2019 Q2 | 4.2 Million SEK | 5.63% |
| 2018 Q3 | 8.81 Million SEK | -3.32% |
| 2018 FY | 8.71 Million SEK | -17.57% |
| 2018 Q1 | 10.06 Million SEK | -4.79% |
| 2018 Q2 | 9.11 Million SEK | -9.43% |
| 2018 Q4 | 8.71 Million SEK | -1.14% |
| 2017 FY | 10.57 Million SEK | -7.06% |
| 2017 Q4 | 10.57 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 11.37 Million SEK | 118.88% |
| 2015 FY | 5.19 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -32.332% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.456% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.456% |
| Arcoma AB | 33.3 Million SEK | 56.301% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 95.586% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.554% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 94.8% |
| CellaVision AB (publ) | 212.32 Million SEK | 93.145% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -2.514% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -111.88% |
| C-Rad AB (publ) | 122.4 Million SEK | 88.11% |
| Duearity AB (publ) | 17.53 Million SEK | 16.977% |
| Dignitana AB (publ) | 37.56 Million SEK | 61.259% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 26.495% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.941% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 29.351% |
| Integrum AB (publ) | 22.07 Million SEK | 34.064% |
| Luxbright AB (publ) | 7 Million SEK | -107.909% |
| Mentice AB (publ) | 163.55 Million SEK | 91.101% |
| OssDsign AB (publ) | 105.25 Million SEK | 86.173% |
| Paxman AB (publ) | 44.5 Million SEK | 67.301% |
| Promimic AB (publ) | 16.15 Million SEK | 9.916% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 76.59% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 31.601% |
| ScandiDos AB (publ) | 37.18 Million SEK | 60.862% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.113% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 66.97% |
| Senzime AB (publ) | 58.06 Million SEK | 74.935% |
| SpectraCure AB (publ) | 14.97 Million SEK | 2.812% |
| Stille AB | 172.64 Million SEK | 91.57% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.603% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 94.192% |